Sign Up Now to Download a Free Research Report on HALO

Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts





Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader.

Halozyme Therapeutics, Inc.

Halozyme Therapeutics shares surged 18.40 percent on nearly five times the average daily volume Thursday to close at $7.98 a share. The company reported data from a clinical trial of its pancreatic cancer drug, PEGPH20, showed it may make tumors more vulnerable to therapy.

Going forward ... (see research report)



RESEARCH REPORT ON HALO Download Free Report Now


Preview Pages of Actual Equity Report

Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader. Research Report on    Research Report on    Research Report on    

Research Report on    Research Report on    Research Report on